60.69
[1]. Dean M Robinson, et al. Paricalcitol: a review of its use in the management of secondary hyperparathyroidism. Drugs. 200;6(4):9-76.
[2]. Dean M Robinson, et al. Spotlight on paricalcitol in secondary hyperparathyroidism. Treat Endocrinol. 200;4():18-6.
[]. Douglas K Atchison, et al. Vitamin D increases plasma renin activity independently of plasma Ca2+ via hypovolemia and β-adrenergic activity. Am J Physiol Renal Physiol. 201 Oct 1;0(8):F1109-17.
[4]. Francesca Tentori, et al. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study. Clin J Am Soc Nephrol. 201 Jan 7;10(1):98-109.
[]. Hubertus Rosery, et al. Health-economic comparison of paricalcitol, calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism during haemodialysis. Clin Drug Investig. 2006;26(11):629-8.
H02-H1-H19-H
P261-P264-P270-P271-P280-P02+P2-P04+P40-P0+P1+P8-P0-P62+P64-P40+P2-P40-P01
![]()
![]()